Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This is a phase I, prospective, open label, dose escalation study of azacitidine in
combination with rituximab, vincristine, and cyclophosphamide for the treatment of refractory
lymphoma. The investigators expect to enroll 12-24 patients in this trial over a 2 year
accrual period.